Task C02: Non-GMP manufacturing of a compound with activity against gram negative bacteria

任务 C02：非 GMP 生产具有抗革兰氏阴性菌活性的化合物

• 批准号: 9916140
• 负责人: MELISSA ALLARD
• 金额: $ 85.2万
• 依托单位: ALBANY MOLECULAR RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-22 至 2020-03-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9916140
• 关键词: Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Drug Kinetics; Evaluation; Gram-Negative Bacteria; In Vitro; Interventional Agent Development; Lead; Microbiology; Safety; Services; Support Contracts; Therapeutic; Toxicology; Toxin; in vivo; pathogen; pre-clinical; product development; programs; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

开发用于传染病的介入药物的非临床服务提供服务，以促进临床前产品开发有希望的引起传染病的病原体和/或毒素的临床前产品。服务包括：临床前产品开发计划和评估；铅识别和发展；化学和GMP制造；体外和体内临床前微生物学，安全性，毒理学和药代动力学。